Patterns of Mobilization of Copper and Iron Following Myocardial Ischemia: Possible Predictive Criteria for Tissue Injury

Berenshtein, Eduard; Mayer, Bernd; Goldberg, Chaya; Kitrossky, Nahum; Chevion, Mordechai

doi:10.1006/jmcc.1997.0535

Cited by 94 publications

(75 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our observation also supports the study by others (12,16,17), because an ischemic event may cause as much or more damage to serum albumin and the surrounding tissue as ischemia itself. Biochemical mechanisms involved in the in vivo alterations to metal-albumin binding during either ischemia or reperfusion may include hypoxia, acidosis, free radical damage, membrane energy-dependent sodium and calcium pump disruptions, and free iron and copper ion exposure (18,19). Most of these conditions occur in vivo within minutes after the onset of acute myocardial ischemia.…”

Section: Discussionmentioning

confidence: 99%

Assay of ischemia‐modified albumin and C‐reactive protein for early diagnosis of acute coronary syndromes

Liyan

Zhang

Yong-hua

et al. 2008

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Diagnosis of cardiac ischemia in patients coming to emergency departments (ED) with symptoms of acute chest pain is often difficult. Many markers are sensitive and specific for the detection of myocardial necrosis but may not rise during reversible myocardial ischemia. Ischemia-modified albumin (IMA) has recently been shown to be a sensitive and early biochemical marker of ischemia. The variation laws were observed by measuring IMA and C-reactive protein (CRP) of 113 patients in ED within 12 hr after onset of chest pain. In the observation, blood was taken for IMA and CRP. Patients underwent standardized triage, diagnostic procedures, and treatment. Results of IMA and CRP were correlated with final diagnoses of nonischemic chest pain (NICP) and acute coronary syndrome (ACS). There were obvious distinction of IMA and CRP levels between the NICP and ACS groups. Receiver operator characteristic (ROC) curve analysis was used to determine the optimal cutoff of this assay for identifying individuals with ACS patients from NICP. The area under the curves of IMA is 0.948. The sensitivity and specificity of albumin cobalt binding (ACB) at a cutoff value of 70.0 units/mL were 94.4% and 82.6%, respectively. The area under the curves of CRP is 0.746. Sensitivity and specificity of CRP at a cutoff value of 3.16 mg/L were 70.0% and 73.9%, respectively. Negative predictive value (NPV) of IMA and CRP for ischemia origin was 79.2% and 38.6%, respectively. IMA may make an early diagnosis of acute coronary ischemia, and will improve the early diagnostic sensitivity and specificity of ACS.

show abstract

Section: Discussionmentioning

confidence: 99%

Assay of ischemia‐modified albumin and C‐reactive protein for early diagnosis of acute coronary syndromes

Liyan

Zhang

Yong-hua

et al. 2008

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…1 Possibly as the result of hypoxia, acidosis, free-radical injury and energydependent membrane disruption, the N-terminal undergoes a decrease in binding capacity in the presence of ischemia. [2][3][4] This alteration can be measured: a set amount of cobalt is added to the patient's serum, after which a colorimetric assay, the albumin-cobalt binding assay, is used to determine the amount of cobalt that remains unbound. An elevated concentration of ischemia-modified albumin (IMA) has, therefore, been proposed as a marker of myocardial ischemic injury.…”

mentioning

confidence: 99%

Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome

Worster

Devereaux²,

Heels‐Ansdell³

et al. 2005

Canadian Medical Association Journal

View full text Add to dashboard Cite

“…Conditions implicated in alteration of metal binding site of human serum albumin are known to occur in vivo within a few minutes after the onset of myocardial ischemia [9,10], as was previously confirmed in patients undergoing percutaneous coronary interventions [11,12]. The study of Bar-Or et al has also shown that acetylation or deletion of one or more amino acids on the N-terminal tripeptide region results in the loss of albumin cobalt binding capacity [11].…”

Section: Discussionmentioning

confidence: 79%

Value of ischemia modified albumin (IMA) for diagnosis of acute coronary syndrome (ACS) in patients with acute chest pain

Dragojević¹,

Kisić²,

Mirić³

et al. 2014

Praxis Med

View full text Add to dashboard Cite

The aim of this study was to evaluate the diagnostic accuracy of ischemia modified albumin (IMA) alone, or in combination with cardiac troponin T (cTnT) and electrocardiogram (ECG) findings for diagnosis of acute coronary syndrome (ACS). The study included patients with acute chest pain suggestive on ACS, recruited within 6 hours from onset. Patients were classified in ACS group and non-ischemic chest pain group (NICP). Of 84 patients, 49 were diagnosed with ACS and 35 with NICP. IMA was significantly higher in ACS group (p<0.0001). The area under receiver operating curve for IMA in ACS diagnosis was 0.95 (p<0.0001). Sensitivity and specificity of IMA for ACS diagnosis were 89.8% and 91.4%, respectively. IMA significantly (p<0.05) improved the sensitivity of ECG and cTnT, alone, and in combination. Sensitivity and negative predictive value of combination of IMA, ECG and cTnT for diagnosis of ACS were 100%. IMA is useful for diagnosis of ACS, in combination with ECG and cTnT.

show abstract

Patterns of Mobilization of Copper and Iron Following Myocardial Ischemia: Possible Predictive Criteria for Tissue Injury

Cited by 94 publications

References 0 publications

Assay of ischemia‐modified albumin and C‐reactive protein for early diagnosis of acute coronary syndromes

Assay of ischemia‐modified albumin and C‐reactive protein for early diagnosis of acute coronary syndromes

Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome

Value of ischemia modified albumin (IMA) for diagnosis of acute coronary syndrome (ACS) in patients with acute chest pain

Contact Info

Product

Resources

About